GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » DiaMedica Therapeutics Inc (NAS:DMAC) » Definitions » Shiller PE Ratio

DiaMedica Therapeutics (DiaMedica Therapeutics) Shiller PE Ratio : (As of May. 24, 2024)


View and export this data going back to 2007. Start your Free Trial

What is DiaMedica Therapeutics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


DiaMedica Therapeutics Shiller PE Ratio Historical Data

The historical data trend for DiaMedica Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DiaMedica Therapeutics Shiller PE Ratio Chart

DiaMedica Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

DiaMedica Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of DiaMedica Therapeutics's Shiller PE Ratio

For the Biotechnology subindustry, DiaMedica Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


DiaMedica Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, DiaMedica Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where DiaMedica Therapeutics's Shiller PE Ratio falls into.



DiaMedica Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

DiaMedica Therapeutics's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, DiaMedica Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.14/131.7762*131.7762
=-0.140

Current CPI (Mar. 2024) = 131.7762.

DiaMedica Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -0.375 100.560 -0.491
201409 -0.358 100.428 -0.470
201412 -0.117 99.070 -0.156
201503 -0.158 99.621 -0.209
201506 -0.161 100.684 -0.211
201509 -0.068 100.392 -0.089
201512 -0.102 99.792 -0.135
201603 -0.400 100.470 -0.525
201606 -0.117 101.688 -0.152
201609 -0.200 101.861 -0.259
201612 -0.070 101.863 -0.091
201703 -0.200 102.862 -0.256
201706 -0.200 103.349 -0.255
201709 -0.150 104.136 -0.190
201712 -0.160 104.011 -0.203
201803 -0.100 105.290 -0.125
201806 -0.220 106.317 -0.273
201809 -0.180 106.507 -0.223
201812 -0.230 105.998 -0.286
201903 -0.270 107.251 -0.332
201906 -0.210 108.070 -0.256
201909 -0.200 108.329 -0.243
201912 -0.210 108.420 -0.255
202003 -0.190 108.902 -0.230
202006 -0.170 108.767 -0.206
202009 -0.190 109.815 -0.228
202012 -0.230 109.897 -0.276
202103 -0.190 111.754 -0.224
202106 -0.170 114.631 -0.195
202109 -0.180 115.734 -0.205
202112 -0.100 117.630 -0.112
202203 -0.130 121.301 -0.141
202206 -0.130 125.017 -0.137
202209 -0.120 125.227 -0.126
202212 -0.140 125.222 -0.147
202303 -0.200 127.348 -0.207
202306 -0.160 128.729 -0.164
202309 -0.120 129.860 -0.122
202312 -0.140 129.419 -0.143
202403 -0.140 131.776 -0.140

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


DiaMedica Therapeutics  (NAS:DMAC) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


DiaMedica Therapeutics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of DiaMedica Therapeutics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


DiaMedica Therapeutics (DiaMedica Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
301 Carlson Parkway, Suite 210, Minneapolis, MN, USA, 55305
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is principally engaged in the business activity of developing treatments for unmet clinical needs or where no therapies are available with a primary focus on chronic kidney disease and acute ischemicstroke. Its pipeline product DM199 is a recombinant form of human tissue kallikrein-1.
Executives
Jan Stahlberg 10 percent owner C/O TRILL INVEST AB, SVEAVAGEN 17 FL 18, STOCKHOLM V7 SE 111 57
Scott Kellen officer: CFO and Secretary 3405 ANNAPOLIS LANE, SUITE 200, MINNEAPOLIS MN 55447
Randall Michael Giuffre director 2 CARLSON PARKWAY, SUITE 260, MINNEAPOLIS MN 55447
Ab Trill 10 percent owner SVEAVAGEN 17, 18TH FLOOR, STOCKHOLM V7 SE-11157
Richard D. Pilnik director 2 CARLSON PARKWAY, SUITE 260, MINNEAPOLIS MN 55447
Dietrich John Pauls director, officer: President and CEO 2 CARLSON PARKWAY, SUITE 260, MINNEAPOLIS MN 55447
Richard Ii Jacinto 10 percent owner 394 SADDLE BACK TRAIL, FRANKLIN LAKES NJ 07417
David J. Wambeke officer: Chief Business Officer 301 CARLSON PARKWAY, SUITE 210, MINNEAPOLIS MN 55305
Private Ab Tomeqt 10 percent owner C/O KINKON AB, BIBLIOTEKSGATAN 25, STOCKHOLM V8 11435
Koch Thomas Von 10 percent owner TOMENTERPRISE AB, BOX 5322, STOCKHOLM V7 102 47
Ab Tomenterprise 10 percent owner C/O EQT PARTNERS AB, BOX 16509, STOCKHOLM V7 103 27
Charles Pauling Semba director TWO CARLSON PARKWAY, SUITE 260, MINNEAPOLIS MN 55447
Richard Kuntz director MEDTRONIC, INC., 710 MEDTRONIC PWKY MS LC 310, MINNEAPOLIS MN 55432
Tanya Lewis director C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVE., NEWTON MA 02459
Julie Vanorsdel Daves officer: SVP Clinical Development Oper. 301 CARLSON PARKWAY, SUITE 210, MINNEAPOLIS MN 55305